Development of cancer vaccines to activate cytotoxic T lymphocytes

Bibliography

• ROSENBERG SA: A New era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity (1999) 10(3):281–287.
   PubMed Web of Science ®Google Scholar
• STEITZ J, BRUCK J, LENZ J, KNOP J, TUTING T: Depletion of CD25+CD4+ T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon a-induced, CD8+ T-cell-dependent immune defense of B16 melanoma. Cancer Res. (2001) 61:8643–8646.
   PubMed Web of Science ®Google Scholar
• GOLGHER D, JONES E, POWRIE F, ELLIOTT T, GALLIMORE A: Depletion of CD25+ regulatory cells uncovers immune responses to shared tumor rejection antigens. Eur. J. ImmunoL (2002) 32:3267–3275.
   PubMed Web of Science ®Google Scholar
• SLIFKA MK, WHITTON JL: Functional avidity maturation of CD8+ T cells without selection of higher affinity TCR. Nat. ImmunoL (2001) 2(8):711–717.
   PubMed Web of Science ®Google Scholar
• KUMARAGURU U, SUVAS S, BIS WAS PS, AZKUR AK, ROUSE BT: Concomitant helper response rescues otherwise low avidity CD8* memory CTLs to become efficient effectors in vivo. ImmunoL (2004) 172:3719–3724.
   Web of Science ®Google Scholar
• ROMIEU R, BARATIN M, KAYIBANDA M, GUILLET JG, VIGUIER M: IFN-y-secreting Th cells regulate both the frequency and avidity of epitope-specific CD8'T lymphocytes induced by peptide immunization: an ex vivo analysis. Int. ImmunoL (1998) 10:1273–1279.
   PubMed Web of Science ®Google Scholar
• ALAN/ SM, TRAVERS PJ, WUNG JL et al.: T-cell-receptor affinity and thymocyte positive selection. Nature (1996) 381:616–620.
   Google Scholar
• FRENCH RR, CHAN HT, TUTT AL, GLENNIE MJ: Improved immunogenicity if a self tumor antigen by covalent linkage to CD40 ligand. Int. J. Cancer (1999) 108:896–703.
   Google Scholar
• ORLEANS-LINDSY JK, DERU A, CRAIG JI, PRENTICE HG, LOWDELL MW: In vitro co-stimulation with anti-CD28 synergizes with IL12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex-vivo generation of CTLs for immunotherapy. Clin. Exp. ImmunoL (2003) 133:467–475.
   PubMed Web of Science ®Google Scholar
• XU D, GU P, PAN PY et al.: NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int. J. Cancer (2004) 109:499–506.
   PubMed Web of Science ®Google Scholar
• LUSTGARTEN J, DOMINGUEZ AL, CUADROS C: The CD8+T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur. j ImmunoL (2004) 34:752–761.
   PubMed Web of Science ®Google Scholar
• OH S, HODGE JW, AHLERS JD, BURKE DS, SCHLOM J, BERZOFSKY JA: Selective induction of high avidity CTL by altering the balance of signals for APC. J. ImmunoL (2003) 170:2523–2530.
   PubMed Web of Science ®Google Scholar
• GUERMONPREZ P, SAVEANU L, KLEIJMEER M et al.: ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature (2003) 425(6956):397–402.
   PubMed Web of Science ®Google Scholar
• HOUDE M, BERTHOLET S, GAGNON E et al.: Phagosomes are competent organelles for antigen cross presentation. Nature (2003) 425(6956):402–406.
   PubMed Web of Science ®Google Scholar
• VALMORI D, GILEADI U, SERVIS C et al.: Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. j Exp. Med. (1999) 189:895–906.
   PubMed Web of Science ®Google Scholar
• GNJATIC S, JAGER E, CHEN Wet al.:CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc. NatL Acad. Sci. USA (2002) 99:11813–11818.
   Google Scholar
• HART I, COLACO C: Immunotherapy:fusion induces tumour rejection. Nature (1997) 388:626–627.
   PubMed Web of Science ®Google Scholar
• GONG J, CHEN D, KASHIWABA M, KUFE M: Induction of anti-tumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. (1997) 3:558–561.
   PubMed Web of Science ®Google Scholar
• KRAUSE SW, NEUMANN C, SORURI A. MAYER S, PETERS JH, ANDREESEN R: The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J. Immunother. (2002) 25:421–428.
   Google Scholar
• KIKUCHI T, AKASAKI Y, IRIE M, HOMMA S, ABET, OHNO T: Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. (2001) 50:337–344.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, DUDLEY ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumour lymphocytes. Proc. NatL Acad. Sci. USA (2004) 101\(Suppl. 2):14639–14645.
   Google Scholar
• MCKAY PF, BAROUCH DH, SANTRA S et al.: Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur. J. ImmunoL (2004) 34:1011–1020.
   PubMed Web of Science ®Google Scholar
• PALMOWSKI MJ, CHOI EM, HERMANS IF et ed.: Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. ImmunoL (2002) 168:4391–4398.
   Google Scholar
• LONCHAY C, VAN DER BRUGGEN P, CONNEROTTE T et al.: Correlation between tumour regression and T cell responses in melanoma patients vaccinated with MAGE antigen. Proc. Natl. Acad. Sci. USA (2004) 101:14631–14638.
   Google Scholar
• BERZOFSKY JA, AHLERS JD, BELYAKOV IM: Strategies for designing and optimising new generation vaccines. Nat. Rev. Immunol (2001) 1:209–217.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. (1998) 4(3):321–327.
   PubMed Web of Science ®Google Scholar
• PHAN GQ, YANG JC, SHERRY RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA (2003) 100:8372–8377.
   PubMed Web of Science ®Google Scholar
• SMITH CL, DUNBAR PR, MIRZA F et al.: Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer (2005) 113:259–266.
   PubMed Web of Science ®Google Scholar
• PALMOWSK MJ, SALIO M, HERMANS IF, DUNBAR PR, CERUNDOLO V: The use of HLA class I tetramers to design a vaccination strategy for melanoma patients. Immunol Rev. (2002) 188:155–163.
   PubMed Web of Science ®Google Scholar
• RIDG WAY D: The first 1000 dendritic cell vaccines. Cancer Invest. (2003) 21:873–886.
   PubMed Web of Science ®Google Scholar
• SRIVASTAVA P: Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol (2002) 20:395–425.
   PubMed Web of Science ®Google Scholar
• BELLI F, TESTORI A, RIVOLTINI L et al.: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol (2002) 20:4169–4180.
   PubMed Web of Science ®Google Scholar
• DATTA SK, RAZ E: Induction of antigen cross-presentation by Toll receptors. Springer Semin. Immunopathol (2005) 26(3):247–255.
   PubMed Web of Science ®Google Scholar
• HE LZ, RAMAKRISHNA V, CONNOLLY JE et al.: A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta. Clin. Cancer Res. (2004) 10:1920–1927.
   PubMed Web of Science ®Google Scholar
• RAMAKRISHNA V, TREML JF, VITALE L et al.: Mannose receptor targeting of tumor antigen pme117 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J. Immunol (2004) 172:2845–2852.
   PubMed Web of Science ®Google Scholar
• REGNAULT A, LANKAR D, LACABANNE Vet al.: Fcy receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I restricted antigen presentation after immune complex internalization. J. Exp. Med. (1999) 189:371–380.
   Google Scholar
• AUSTIN EB, ROBINS RA, DURRANT LG, PRICE MR, BALDWIN RW: Human monoclonal anti-idiotypic antibody to the tumour associated antibody 791T/36. Immunology (1989) 67:525–530.
   PubMed Web of Science ®Google Scholar
• AUSTIN EB, ROBINS RA, BALDWIN RW, DURRANT LG: Induction of delayed-hypersensitivity to human tumor-cells with a human monoclonal antiidiotypic antibody. J. Nail. Cancer Inst. (1991) 83(17):1245–1248.
   PubMed Web of Science ®Google Scholar
• ROBINS RA, DENTON GW, HARDCASTLE JD, AUSTIN EB, BALDWIN RW, DURRANT LG: Antitumor immune-response and interleukin-2 production induced in colorectal-cancer patients by immunization with human monoclonal antiidiotypic antibody. Cancer Res. (1991) 51(19):5425–5429.
   PubMed Web of Science ®Google Scholar
• DENTON GW, ROBBINS RA, DURRANT LG et al: Cell-mediated response in vitro after immunization of colorectal cancer patients with a human monoclonal antiidiotypic antibody. Gut (1991) 32(5):A557–A557.
   Web of Science ®Google Scholar
• DURRANT LG, BUCKLEY TJ, DENTON GW et al: Enhanced cell mediated tumour killing in patients immunised with human monoclonal anti-idiotypic antibody 105AD7. Cancer Res. (1994) 54:4837–4840.
   PubMed Web of Science ®Google Scholar
• DURRANT LG, ARMSTRONG CM, BUCKLEY D et al: A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Clin. Cancer Res. (2000) 62(2):422–430.
   Google Scholar
• DURRANT LG, SPENDLOVE I, BUCKLEY DJ, ROBINS RA: 105AD7 cancer vaccine stimulates anti-tumour helper and cytotoxic T cell responses in HLA-A1,3,24 and HLA-DR 1,3,7 colorectal cancer patients. Int. J. Cancer (2000) 85(1):87–92.
   PubMed Web of Science ®Google Scholar
• SPENDLOVE I, LI L, CARMICHAEL J, DURRANT LG: Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Res. (1999) 59(10):2282–2286.
   Google Scholar
• SPENDLOVE I, LI L, POTTER Vet al: A therapeutic human anti-idiotypic antibody (105AD7) mimics CD55 (decay accelerating factor) in three distinct regions. Eur. J. Immunol (2000) 30:2944–2953.
   PubMed Web of Science ®Google Scholar
• MAXWELL-ARMSTRONG CA, DURRANT LG, ROBINS RA et ell.: Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotype monoclonal antibody 105AD7. Gut (1999) 45:593–598.
   Google Scholar
• MAXWELL-ARMSTRONG CA, DURRANT LG, SCHOLEFIELD JH: Immunotherapy for colorectal cancer. Am. J. Surg. (1999) 177(4):344–348.
   PubMed Web of Science ®Google Scholar
• MAXWELL-ARMSTRONG CA, DURRANT LG, BUCKLEY TJ et al: Randomized double-blind Phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br. J. Cancer (2001) 84(11):1443–1446.
   PubMed Web of Science ®Google Scholar
• AMIN S, ROBINS RA, MAXWELL-ARMSTRONG C, SCHOLEFIELD J, DURRANT LG: Vaccine induced apoptosis: a novel clinical trial endpoint? Cancer Res. (2000) 63:3132–3136.
   Google Scholar
• DURRANT LG, PARSONS T, MOSS R et al: Human anti-idiotypic antibodies can be good immunogens as they target Fc receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses. Int. J. Cancer (2001) 92:414–420.
   PubMed Web of Science ®Google Scholar
• DURRANT LG, DENTON GW, JACOBS E et al: An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumors. Int. J. Cancer (1992) 50(5):811–816.
   PubMed Web of Science ®Google Scholar
• PARSONS T, SPENDLOVE I, NIRULA Ret al: A novel CEA vaccine stimulates T cell proliferation, gammaIEN secret and CFA specific CTL responses. Vaccine (2004) 22(25-26):3487–3494.
   PubMed Web of Science ®Google Scholar
• SCHUURHUIS DH, IOAN-FACSINAY A, NAGELKERKEN B et al: Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. Immunol (2002) 168(5):2240–2246.
   Web of Science ®Google Scholar
• YOU Z, HESTER J, ROLLINS Let al.: A retrogen strategy for presentation of an intracellular tumour antigen as an exogenous antigen by dendritic cells induces potent antitumour T helper and CTL responses. Cancer Res. (2001) 61:197–205.
   Google Scholar
• YOU Z, HUANG X, HESTER J, TOH HC, CHEN SY: Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res. (2001) 61:3704–3711.
   PubMed Web of Science ®Google Scholar
• RAMAGE JM, METHERINGHAM R, CONN A et al.: Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2. Int. J. Cancer (2004) 110:245–250.
   PubMed Web of Science ®Google Scholar
• RAMAGE JM, METHERINGHAM R, MOSS RS et al.: DNA-Fc Fusion Vaccine targeting the endothelial antigen Tie-2. Br. J. Cancer (2003) 88\(Suppl. 1):538.
   Google Scholar
• TRAN R, HAND PH, GREINER JW, PESTKA S, SCHOLM J: Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons. J. Interferon Res. (1988) 8:75–88.
   PubMedGoogle Scholar
• DONG H, STROME SE, SALOMAO D et al.: Tumor-associated B7-Hi promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. (2002) 8(8):793–800.
   PubMed Web of Science ®Google Scholar
• ROBERTS Al, LEE L, SCHWARZ E et al.:NKG2D receptors induced by IL-15 costimulate CD28-ngeative effector CTL in the tissue microenvironment. J. Immunol. (2001) 167:5527–5530.
   PubMed Web of Science ®Google Scholar
• NIETHAMMER AG, XIANG R, RUEHLMANN JM et al.: Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res. (2001) 61:6178–6184.
   PubMed Web of Science ®Google Scholar
• GARNET CT, PALENA C, CHAKARBORTY M et al.: Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. (2004) 64:7985–7994.
   PubMed Web of Science ®Google Scholar
• CHAKARBORTY M, ABRAMS SI, COLEMAN CN et al.: External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine mediated T-cell killing. Cancer Res. (2004) 64:4328–4337.
   PubMed Web of Science ®Google Scholar
• MACHIELS JP, REILLY RT, EMENS LA et al.: Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumour immune responses of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerised mice. Cancer Res. (2001) 61:3689–3697.
   PubMed Web of Science ®Google Scholar
• HILL SC, YOUDE SJ, MAN S et al.: Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. Immunol. (2005) 174:41–50.
   Web of Science ®Google Scholar